|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: B3GAT3 |
Gene summary for B3GAT3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | B3GAT3 | Gene ID | 26229 |
| Gene name | beta-1,3-glucuronyltransferase 3 | |
| Gene Alias | GLCATI | |
| Cytomap | 11q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q5U676 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26229 | B3GAT3 | LZE2T | Human | Esophagus | ESCC | 1.54e-09 | 6.09e-01 | 0.082 |
| 26229 | B3GAT3 | LZE4T | Human | Esophagus | ESCC | 1.73e-10 | 2.94e-01 | 0.0811 |
| 26229 | B3GAT3 | LZE7T | Human | Esophagus | ESCC | 4.12e-10 | 8.05e-01 | 0.0667 |
| 26229 | B3GAT3 | LZE8T | Human | Esophagus | ESCC | 5.76e-12 | 2.31e-01 | 0.067 |
| 26229 | B3GAT3 | LZE20T | Human | Esophagus | ESCC | 3.16e-04 | 1.33e-01 | 0.0662 |
| 26229 | B3GAT3 | LZE22T | Human | Esophagus | ESCC | 5.75e-07 | 4.76e-01 | 0.068 |
| 26229 | B3GAT3 | LZE24T | Human | Esophagus | ESCC | 4.32e-30 | 7.47e-01 | 0.0596 |
| 26229 | B3GAT3 | LZE6T | Human | Esophagus | ESCC | 2.17e-09 | 4.93e-01 | 0.0845 |
| 26229 | B3GAT3 | P1T-E | Human | Esophagus | ESCC | 2.04e-06 | 2.44e-01 | 0.0875 |
| 26229 | B3GAT3 | P2T-E | Human | Esophagus | ESCC | 4.87e-46 | 8.16e-01 | 0.1177 |
| 26229 | B3GAT3 | P4T-E | Human | Esophagus | ESCC | 3.59e-50 | 1.02e+00 | 0.1323 |
| 26229 | B3GAT3 | P5T-E | Human | Esophagus | ESCC | 1.97e-42 | 8.50e-01 | 0.1327 |
| 26229 | B3GAT3 | P8T-E | Human | Esophagus | ESCC | 3.98e-36 | 6.65e-01 | 0.0889 |
| 26229 | B3GAT3 | P9T-E | Human | Esophagus | ESCC | 1.34e-29 | 5.93e-01 | 0.1131 |
| 26229 | B3GAT3 | P10T-E | Human | Esophagus | ESCC | 9.47e-42 | 7.25e-01 | 0.116 |
| 26229 | B3GAT3 | P11T-E | Human | Esophagus | ESCC | 9.90e-25 | 9.81e-01 | 0.1426 |
| 26229 | B3GAT3 | P12T-E | Human | Esophagus | ESCC | 2.76e-36 | 7.13e-01 | 0.1122 |
| 26229 | B3GAT3 | P15T-E | Human | Esophagus | ESCC | 4.29e-23 | 4.58e-01 | 0.1149 |
| 26229 | B3GAT3 | P16T-E | Human | Esophagus | ESCC | 2.19e-34 | 7.62e-01 | 0.1153 |
| 26229 | B3GAT3 | P17T-E | Human | Esophagus | ESCC | 2.11e-15 | 6.94e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003238811 | Liver | Cirrhotic | positive regulation of intracellular transport | 92/4634 | 202/18723 | 8.60e-11 | 4.66e-09 | 92 |
| GO:009031611 | Liver | Cirrhotic | positive regulation of intracellular protein transport | 77/4634 | 160/18723 | 1.17e-10 | 6.21e-09 | 77 |
| GO:003238621 | Liver | HCC | regulation of intracellular transport | 231/7958 | 337/18723 | 1.99e-22 | 3.40e-20 | 231 |
| GO:003315721 | Liver | HCC | regulation of intracellular protein transport | 165/7958 | 229/18723 | 8.37e-20 | 1.15e-17 | 165 |
| GO:003238821 | Liver | HCC | positive regulation of intracellular transport | 148/7958 | 202/18723 | 5.15e-19 | 6.66e-17 | 148 |
| GO:009031621 | Liver | HCC | positive regulation of intracellular protein transport | 121/7958 | 160/18723 | 1.27e-17 | 1.39e-15 | 121 |
| GO:190495122 | Liver | HCC | positive regulation of establishment of protein localization | 207/7958 | 319/18723 | 3.95e-16 | 3.29e-14 | 207 |
| GO:005122222 | Liver | HCC | positive regulation of protein transport | 194/7958 | 303/18723 | 2.41e-14 | 1.56e-12 | 194 |
| GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
| GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
| GO:003238615 | Oral cavity | OSCC | regulation of intracellular transport | 218/7305 | 337/18723 | 6.91e-22 | 1.41e-19 | 218 |
| GO:003315718 | Oral cavity | OSCC | regulation of intracellular protein transport | 155/7305 | 229/18723 | 1.05e-18 | 1.28e-16 | 155 |
| GO:190495119 | Oral cavity | OSCC | positive regulation of establishment of protein localization | 196/7305 | 319/18723 | 2.89e-16 | 2.20e-14 | 196 |
| GO:005122219 | Oral cavity | OSCC | positive regulation of protein transport | 187/7305 | 303/18723 | 7.37e-16 | 5.49e-14 | 187 |
| GO:003238818 | Oral cavity | OSCC | positive regulation of intracellular transport | 134/7305 | 202/18723 | 2.82e-15 | 1.88e-13 | 134 |
| GO:009031610 | Oral cavity | OSCC | positive regulation of intracellular protein transport | 110/7305 | 160/18723 | 2.10e-14 | 1.19e-12 | 110 |
| GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
| GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00532 | Oral cavity | OSCC | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 16/3704 | 21/8465 | 2.61e-03 | 6.77e-03 | 3.45e-03 | 16 |
| hsa005321 | Oral cavity | OSCC | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 16/3704 | 21/8465 | 2.61e-03 | 6.77e-03 | 3.45e-03 | 16 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| B3GAT3 | SNV | Missense_Mutation | novel | c.87N>T | p.Gln29His | p.Q29H | O94766 | protein_coding | deleterious(0.01) | probably_damaging(0.936) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| B3GAT3 | SNV | Missense_Mutation | rs868665260 | c.928N>T | p.Arg310Trp | p.R310W | O94766 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| B3GAT3 | SNV | Missense_Mutation | novel | c.94N>A | p.Asp32Asn | p.D32N | O94766 | protein_coding | tolerated(0.08) | probably_damaging(0.994) | TCGA-EW-A3U0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| B3GAT3 | SNV | Missense_Mutation | novel | c.674G>A | p.Arg225Gln | p.R225Q | O94766 | protein_coding | tolerated(0.11) | possibly_damaging(0.691) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| B3GAT3 | SNV | Missense_Mutation | rs562657438 | c.632G>A | p.Arg211His | p.R211H | O94766 | protein_coding | deleterious(0.03) | benign(0.028) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| B3GAT3 | SNV | Missense_Mutation | c.563N>T | p.Gly188Val | p.G188V | O94766 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| B3GAT3 | SNV | Missense_Mutation | novel | c.17A>T | p.Lys6Met | p.K6M | O94766 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| B3GAT3 | SNV | Missense_Mutation | novel | c.583N>A | p.Asp195Asn | p.D195N | O94766 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| B3GAT3 | SNV | Missense_Mutation | novel | c.872N>A | p.Pro291His | p.P291H | O94766 | protein_coding | tolerated(0.06) | possibly_damaging(0.618) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| B3GAT3 | SNV | Missense_Mutation | rs768684929 | c.622N>T | p.Arg208Cys | p.R208C | O94766 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |